Outcome variables before and after day 110 in patients who received fluconazole compared with placebo
| Outcome . | On or before day 110 (%)* . | P† . | After day 110 (%)‡ . | P† . |
|---|---|---|---|---|
| Deaths | ||||
| Placebo | 52 (35) | .004 | 55 (57) | .043 |
| Fluconazole | 31 (20) | 53 (44) | ||
| Relapse | ||||
| Placebo | 8 (5) | .37 | 31 (32) | .09 |
| Fluconazole | 5 (3) | 27 (22) | ||
| Acute GVHD grade ≥ 2 | ||||
| Placebo | 82 (55) | .17 | na | na |
| Fluconazole | 96 (63) | na | ||
| Chronic GVHD2-153 | ||||
| Placebo | 21 (14) | .49 | 27 (28) | .75 |
| Fluconazole | 26 (17) | 32 (21) |
| Outcome . | On or before day 110 (%)* . | P† . | After day 110 (%)‡ . | P† . |
|---|---|---|---|---|
| Deaths | ||||
| Placebo | 52 (35) | .004 | 55 (57) | .043 |
| Fluconazole | 31 (20) | 53 (44) | ||
| Relapse | ||||
| Placebo | 8 (5) | .37 | 31 (32) | .09 |
| Fluconazole | 5 (3) | 27 (22) | ||
| Acute GVHD grade ≥ 2 | ||||
| Placebo | 82 (55) | .17 | na | na |
| Fluconazole | 96 (63) | na | ||
| Chronic GVHD2-153 | ||||
| Placebo | 21 (14) | .49 | 27 (28) | .75 |
| Fluconazole | 26 (17) | 32 (21) |
GVHD indicates graft-versus-host disease; cGVHD, chronic graft-versus-host disease.
Among 148 patients in placebo group and 152 patients in fluconazole group.
Calculated from χ2 tests.
Among 96 placebo and 122 fluconazole arm patients alive at day 110 after transplant.
Only clinically extensive cGVHD is included.